Review ArticleReview Article
Open Access

The evolvement of breast cancer therapies

What we have done and where all these head off

Ika Nurlaila and Sabar Pambudi
Saudi Medical Journal April 2024, 45 (4) 331-340; DOI: https://doi.org/10.15537/smj.2024.45.4.20230492

References

  1. 1.↵
    1. Momenimovahed Z,
    2. Salehiniya H.
    Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press) 2019; 11: 151-164.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Wilkinson L,
    2. Gathani T.
    Understanding breast cancer as a global health concern. Br J Radiol 2022; 95: 20211033.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Ugai T,
    2. Sasamoto N,
    3. Lee HY,
    4. Ando M,
    5. Song M,
    6. Tamimi RM, et al.
    Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat Rev Clin Oncol 2022; 19: 656-673.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Almansour NM.
    Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence. Front Mol Biosci 2022; 9: 836417.
    OpenUrl
  5. 5.↵
    1. Yin L,
    2. Duan JJ,
    3. Bian XW,
    4. Yu SC.
    Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 2020; 22: 61.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Liu L,
    2. Hao X,
    3. Song Z,
    4. Zhi X,
    5. Zhang S,
    6. Zhang J.
    Correlation between family history and characteristics of breast cancer. Sci Rep 2021; 11: 6360.
    OpenUrl
  7. 7.↵
    1. Braithwaite D,
    2. Miglioretti DL,
    3. Zhu W,
    4. Demb J,
    5. Trentham-Dietz A,
    6. Sprague B, et al.
    Family history and breast cancer risk among older women in the breast cancer surveillance consortium cohort. JAMA Intern Med 2018; 178: 494-501.
    OpenUrl
  8. 8.↵
    1. Magnusson C,
    2. Colditz G,
    3. Rosner B,
    4. Bergström R,
    5. Persson I.
    Association of family history and other risk factors with breast cancer risk (Sweden). Cancer Causes Control 1998; 9: 259-267.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Colditz GA,
    2. Kaphingst KA,
    3. Hankinson SE,
    4. Rosner B.
    Family history and risk of breast cancer: nurses’ health study. Breast Cancer Res Treat 2012; 133: 1097-1104.
    OpenUrlPubMed
  10. 10.↵
    1. Loomans-Kropp HA,
    2. Umar A.
    Cancer prevention and screening: the next step in the era of precision medicine. NPJ Precis Oncol 2019; 3: 3.
    OpenUrl
  11. 11.↵
    1. Witkiewicz AK,
    2. Knudsen ES.
    Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. Breast Cancer Res 2014; 16: 207.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Chano T,
    2. Ikebuchi K,
    3. Tomita Y,
    4. Jin Y,
    5. Inaji H,
    6. Ishitobi M, et al.
    RB1CC1 together with RB1 and p53 predicts long-term survival in Japanese breast cancer patients. PLoS One 2010; 5: e15737.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Ikebuchi K,
    2. Chano T,
    3. Ochi Y,
    4. Tameno H,
    5. Shimada T,
    6. Hisa Y, et al.
    RB1CC1 activates the promoter and expression of RB1 in human cancer. Int J Cancer 2009; 125: 861-867.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Lohmann DR.
    RB1 gene mutations in retinoblastoma. Hum Mutat 1999; 14: 283-288.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Yun J,
    2. Li Y,
    3. Xu CT,
    4. Pan BR.
    Epidemiology and Rb1 gene of retinoblastoma. Int J Ophthalmol 2011; 4: 103-109.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Berge EO,
    2. Knappskog S,
    3. Lillehaug JR,
    4. Lønning PE.
    Alterations of the retinoblastoma gene in metastatic breast cancer. Clin Exp Metastasis 2011; 28: 319-326.
    OpenUrlPubMed
  17. 17.↵
    1. Robinson TJ,
    2. Liu JC,
    3. Vizeacoumar F,
    4. Sun T,
    5. Maclean N,
    6. Egan SE, et al.
    RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS One 2013; 8: e78641.
    OpenUrlCrossRef
  18. 18.↵
    1. Witkiewicz AK,
    2. Knudsen ES.
    Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. Breast Cancer Res 2014; 16: 207.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Lawrence MS,
    2. Stojanov P,
    3. Mermel CH,
    4. Robinson JT,
    5. Garraway LA,
    6. Golub TR, et al.
    Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495-501.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Bertucci F,
    2. Finetti P,
    3. Guille A,
    4. Adélaïde J,
    5. Garnier S,
    6. Carbuccia N, et al.
    Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget 2016; 7: 27208-27219.
    OpenUrl
  21. 21.↵
    1. Dunlap J,
    2. Le C,
    3. Shukla A,
    4. Patterson J,
    5. Presnell A,
    6. Heinrich MC, et al.
    Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 2010; 120: 409-418.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Miller TW,
    2. Rexer BN,
    3. Garrett JT,
    4. Arteaga CL.
    Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011; 13: 224.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Ma H,
    2. Bernstein L,
    3. Ross RK,
    4. Ursin G.
    Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison. Breast Cancer Res 2006; 8: R39.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Parise CA,
    2. Caggiano V.
    Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol 2014; 2014: 469251.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Wójcik C,
    2. Bury M,
    3. Stoklosa T,
    4. Giermasz A,
    5. Feleszko W,
    6. Mlynarczuk I, et al.
    Lovastatin and simvastatin are modulators of the proteasome. Int J Biochem Cell Biol 2000; 32: 957-965.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Yao H,
    2. He G,
    3. Yan S,
    4. Chen C,
    5. Song L,
    6. Rosol TJ, et al.
    Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017; 8: 1913-1924.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Elwan A,
    2. Abdelrahman AE,
    3. Alnagar AA,
    4. Abdelhamid MI,
    5. Nawar N.
    Clinicopathological features and treatment challenges in triple negative breast cancer patients: a retrospective cohort study. Turk Patoloji Derg 2021; 37: 121-129.
    OpenUrl
  28. 28.↵
    1. Wu S,
    2. Gottumukkala V,
    3. Coelho R,
    4. Moore LJ,
    5. Kelly V,
    6. Ilovich O, et al.
    Development of targeted radiotherapy for triple negative breast cancer. J Clin Oncol 2018; 36: e13112-e13112.
    OpenUrl
  29. 29.↵
    1. Czajka ML,
    2. Pfeifer C.
    Breast cancer surgery. [Updated 2024; accessed 2023 Apr 27]. Available from: https://pubmed.ncbi.nlm.nih.gov/31971717/
  30. 30.↵
    1. Admoun C,
    2. Mayrovitz H.
    Choosing mastectomy vs. lumpectomy-with-radiation: experiences of breast cancer survivors. Cureus 2021; 13: e18433.
    OpenUrl
  31. 31.↵
    Mastectomy or lumpectomy? The choice of operation for clinical stages I and II breast cancer. The steering committee on clinical practice guidelines for the care and treatment of breast cancer. Canadian Association of Radiation Oncologists. CMAJ 1998; 158: S15-S21.
    OpenUrlPubMed
  32. 32.↵
    1. Wickerham DL,
    2. O’Connell MJ,
    3. Costantino JP,
    4. Cronin WM,
    5. Paik S,
    6. Geyer CE Jr., et al.
    The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project. Semin Oncol 2008; 35: 522-529.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Kimball CC,
    2. Nichols CI,
    3. Vose JG,
    4. Peled AW.
    Trends in lumpectomy and oncoplastic breast-conserving surgery in the US, 2011-2016. Ann Surg Oncol 2018; 25: 3867-3873.
    OpenUrl
  34. 34.↵
    1. Kaufman CS,
    2. Calhoun K.
    Oncoplastic breast surgery. [Updated 2022; accessed 2023 Apr 27]. Available from: https://www.uptodate.com/contents/oncoplastic-breast-surgery#H14027158
  35. 35.↵
    1. Cheng X,
    2. Zhang H,
    3. Hamad A,
    4. Huang H,
    5. Tsung A.
    Surgery-mediated tumor-promoting effects on the immune microenvironment. Semin Cancer Biol 2022; 86: 408-419.
    OpenUrl
  36. 36.↵
    1. Ananth AA,
    2. Tai LH,
    3. Lansdell C,
    4. Alkayyal AA,
    5. Baxter KE,
    6. Angka L, et al.
    Surgical stress abrogates pre-existing protective T cell mediated anti-tumor immunity leading to postoperative cancer recurrence. PLoS One 2016; 11: e0155947.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Haussmann J,
    2. Corradini S,
    3. Nestle-Kraemling C,
    4. Bölke E,
    5. Njanang FJD,
    6. Tamaskovics B, et al.
    Recent advances in radiotherapy of breast cancer. Radiat Oncol 2020; 15: 71.
    OpenUrl
  38. 38.
    1. Neugut AI,
    2. Weinberg MD,
    3. Ahsan H,
    4. Rescigno J.
    Carcinogenic effects of radiotherapy for breast cancer. Oncology (Williston Park) 1999; 13: 1245-1256.
    OpenUrl
  39. 39.
    1. Taylor CW,
    2. Kirby AM.
    Cardiac side-effects from breast cancer radiotherapy. Clin Oncol (R Coll Radiol) 2015; 27: 621-629.
    OpenUrlCrossRefPubMed
  40. 40.
    1. Janssen S,
    2. Käsmann L,
    3. Fahlbusch FB,
    4. Rades D,
    5. Vordermark D.
    Side effects of radiotherapy in breast cancer patients: the internet as an information source. Strahlenther Onkol 2018; 194: 136-142.
    OpenUrl
  41. 41.↵
    1. Senkus-Konefka E,
    2. Jassem J.
    Complications of breast-cancer radiotherapy. Clin Oncol (R Coll Radiol) 2006; 18: 229-235.
    OpenUrlPubMed
  42. 42.↵
    1. Jiang H,
    2. Wang H,
    3. De Ridder M.
    Targeting antioxidant enzymes as a radiosensitizing strategy. Cancer Lett 2018; 438: 154-164.
    OpenUrl
  43. 43.↵
    1. Vanpouille-Box C,
    2. Alard A,
    3. Aryankalayil MJ,
    4. Sarfraz Y,
    5. Diamond JM,
    6. Schneider RJ, et al.
    DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 2017; 8: 15618.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Riegler J,
    2. Gill H,
    3. Ogasawara A,
    4. Hedehus M,
    5. Javinal V,
    6. Oeh J, et al.
    VCAM-1 density and tumor perfusion predict T-cell infiltration and treatment response in preclinical models. Neoplasia 2019; 21: 1036-1050.
    OpenUrlPubMed
  45. 45.↵
    1. Suesada MM,
    2. Carvalho HA,
    3. Albuquerque ALP,
    4. Salge JM,
    5. Stuart SR,
    6. Takagaki TY.
    Impact of thoracic radiotherapy on respiratory function and exercise capacity in patients with breast cancer. J Bras Pneumol 2018; 44: 469-476.
    OpenUrl
  46. 46.↵
    1. Piroth MD,
    2. Baumann R,
    3. Budach W,
    4. Dunst J,
    5. Feyer P,
    6. Fietkau R, et al.
    Heart toxicity from breast cancer radiotherapy: current findings, assessment, and prevention. Strahlenther Onkol 2019; 195: 1-12.
    OpenUrl
  47. 47.↵
    1. He MY,
    2. Rancoule C,
    3. Rehailia-Blanchard A,
    4. Espenel S,
    5. Trone JC,
    6. Bernichon E, et al.
    Radiotherapy in triple-negative breast cancer: current situation and upcoming strategies. Crit Rev Oncol Hematol 2018; 131: 96-101.
    OpenUrl
  48. 48.↵
    Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    1. Wu TC,
    2. McCloskey SA.
    Established and new horizons in radiotherapy for breast cancer. Ther Adv Med Oncol 2023; 15: 17588359231161415.
    OpenUrl
  50. 50.↵
    1. Telli ML,
    2. Sledge GW.
    The future of breast cancer systemic therapy: the next 10 years. J Mol Med (Berl) 2015; 93: 119-125.
    OpenUrl
  51. 51.↵
    1. Tutt ANJ,
    2. Garber JE,
    3. Kaufman B,
    4. Viale G,
    5. Fumagalli D,
    6. Rastogi P, et al.
    Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021; 384: 2394-2405.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Robson M,
    2. Im SA,
    3. Senkus E,
    4. Xu B,
    5. Domchek SM,
    6. Masuda N, et al.
    Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017; 377: 523-533.
    OpenUrlCrossRefPubMed
  53. 53.
    1. Zhang Y,
    2. Zheng J.
    Functions of immune checkpoint molecules beyond immune evasion. Adv Exp Med Biol 2020; 1248: 201-226.
    OpenUrl
  54. 54.
    1. Wei SC,
    2. Duffy CR,
    3. Allison JP.
    Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 2018; 8: 1069-1086.
    OpenUrlAbstract/FREE Full Text
  55. 55.
    1. Smith HE,
    2. Frei BL.
    Chapter 35 - Drugs that act on the immune system: cytokines and monoclonal antibodies. [Updated 2019; accessed 2023 Apr 23]. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0378608019300303
  56. 56.
    1. Winer EP,
    2. Lipatov O,
    3. Im SA,
    4. Goncalves A,
    5. Muñoz-Couselo E,
    6. Lee KS, et al.
    Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 499-511.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Cortes J,
    2. Rugo HS,
    3. Cescon DW,
    4. Im SA,
    5. Yusof MM,
    6. Gallardo C, et al.
    Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 2022; 387: 217-226.
    OpenUrlCrossRefPubMed
  58. 58.
    1. Nurlaila I,
    2. Roh K,
    3. Yeom CH,
    4. Kang H,
    5. Lee S.
    Acquired lymphedema: molecular contributors and future directions for developing intervention strategies. Front Pharmacol 2022; 13: 873650.
    OpenUrl
  59. 59.↵
    1. Joo WD,
    2. Visintin I,
    3. Mor G.
    Targeted cancer therapy--are the days of systemic chemotherapy numbered? Maturitas 2013; 76: 308-314.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Masoud V,
    2. Pagès G.
    Targeted therapies in breast cancer: new challenges to fight against resistance. World J Clin Oncol 2017; 8: 120-134.
    OpenUrl
  61. 61.↵
    1. Hasskarl J. Everolimus
    . Recent Results Cancer Res 2018; 211: 101-123.
    OpenUrl
  62. 62.↵
    1. Garcia J,
    2. Hurwitz HI,
    3. Sandler AB,
    4. Miles D,
    5. Coleman RL,
    6. Deurloo R, et al.
    Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 2020; 86: 102017.
    OpenUrlCrossRefPubMed
  63. 63.↵
    1. Wedam S,
    2. Fashoyin-Aje L,
    3. Gao X,
    4. Bloomquist E,
    5. Tang S,
    6. Sridhara R, et al.
    FDA approval summary: ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer. Clin Cancer Res 2020; 26: 4180-4185.
    OpenUrlAbstract/FREE Full Text
  64. 64.↵
    1. Schlam I,
    2. Swain SM.
    HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. NPJ Breast Cancer 2021; 7: 56.
    OpenUrl
  65. 65.↵
    1. Mäenpää JU,
    2. Ala-Fossi SL.
    Toremifene in postmenopausal breast cancer. Efficacy, safety and cost. Drugs Aging 1997; 11: 261-270.
    OpenUrlPubMedWeb of Science
  66. 66.↵
    1. Marra A,
    2. Curigliano G.
    Adjuvant and neoadjuvant treatment of triple-negative breast cancer with chemotherapy. Cancer J 2021; 27: 41-49.
    OpenUrl
  67. 67.↵
    1. Isakoff SJ.
    Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010; 16: 53-61.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords